Answers are grounded in this paper and cite their sources.
This mini-review will provide an overview on the recent design principles and structure-activity-relationship of β-selective thyroid hormone receptor (TR) agonists. The prospects for the treatment of metabolic diseases as dyslipidemia with TRβ-selective ligands are considerable enough so as to avoid cardiovascular acceleration mediated through TRα.
No takes yet. Share an insight, caveat, or question.
Malm et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: